Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01894516




Registration number
NCT01894516
Ethics application status
Date submitted
4/07/2013
Date registered
10/07/2013
Date last updated
16/12/2020

Titles & IDs
Public title
Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Participants (DARWIN2)
Scientific title
Randomized, Double-blind, Placebo-controlled, Multicenter, Phase IIb Dose Finding Study of GLPG0634 Administered for 24 Weeks as Monotherapy to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate (MTX) Alone
Secondary ID [1] 0 0
GLPG0634-CL-204 (DARWIN2)
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Rheumatoid Arthritis 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Osteoarthritis
Inflammatory and Immune System 0 0 0 0
Rheumatoid arthritis

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - GLPG0634
Treatment: Drugs - Placebo

Placebo comparator: Placebo - Participants received GLPG0634 matching placebo capsules, orally, once daily (QD) during Weeks 1 to 12 and GLPG0634 100 milligram (mg) QD during Weeks 13 to 24.

Experimental: GLPG0634 50 mg QD - Participants received GLPG0634 50 mg capsules, orally, QD during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 50 mg QD while nonresponders were re-randomized to 100 mg QD during Weeks 13 to 24.

Experimental: GLPG0634 100 mg QD - Participants received GLPG0634 100 mg capsules, orally, QD during Weeks 1 to 24.

Experimental: GLPG0634 200 mg QD - Participants received GLPG0634 200 mg capsules, orally, QD during Weeks 1 to 24.


Treatment: Drugs: GLPG0634
GLPG0634 capsules.

Treatment: Drugs: Placebo
Placebo capsules.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants Achieving an American College of Rheumatology (ACR) 20 Response at Week 12
Timepoint [1] 0 0
Week 12
Secondary outcome [1] 0 0
Percentage of Participants Achieving an ACR20 Response at Week 24
Timepoint [1] 0 0
Week 24
Secondary outcome [2] 0 0
Percentage of Participants Achieving an ACR50 Response at Weeks 1, 2, 4, 8, 12, and 24
Timepoint [2] 0 0
Weeks 1, 2, 4, 8, 12, and 24
Secondary outcome [3] 0 0
Percentage of Participants Achieving an ACR70 Response at Weeks 1, 2, 4, 8, 12, and 24
Timepoint [3] 0 0
Weeks 1, 2, 4, 8, 12, and 24
Secondary outcome [4] 0 0
ACR N% Improvement (ACR-N) Response at Weeks 1, 2, 4, 8, 12, and 24
Timepoint [4] 0 0
Weeks 1, 2, 4, 8, 12, and 24
Secondary outcome [5] 0 0
Percentage of Participants With Disease Activity Score 28 Joints Corrected for CRP (DAS28 (CRP)) European League Against Rheumatism (EULAR) Response at Weeks 1, 2, 4, 8, 12, and 24
Timepoint [5] 0 0
Weeks 1, 2, 4, 8, 12, and 24
Secondary outcome [6] 0 0
Percentage of Participants Achieving ACR/EULAR Remission at Weeks 2, 4, 8, 12, and 24
Timepoint [6] 0 0
Weeks 4, 8, 12, and 24
Secondary outcome [7] 0 0
Change From Baseline in Simplified Disease Activity Index (SDAI) at Weeks 1, 2, 4, 8, 12, and 24
Timepoint [7] 0 0
Baseline and Weeks 1, 2, 4, 8, 12, and 24
Secondary outcome [8] 0 0
Change From Baseline in Clinical Disease Activity Index (CDAI) at Weeks 1, 2, 4, 8, 12, and 24
Timepoint [8] 0 0
Baseline and Weeks 1, 2, 4, 8, 12, and 24
Secondary outcome [9] 0 0
Change From Baseline in Quality of Life Using the Functional Assessment of Chronic Illness Therapy (FACIT) at Weeks 4, 12, and 24
Timepoint [9] 0 0
Baseline and Weeks 4, 12, and 24
Secondary outcome [10] 0 0
Change From Baseline in Quality of Life Using the Short Form-36 (SF-36) Scores at Weeks 4, 12, and 24
Timepoint [10] 0 0
Baseline and Weeks 4, 12, and 24

Eligibility
Key inclusion criteria
* male or female subjects who are =18 years of age on the day of signing informed consent,
* have a diagnosis of RA since at least 6 months and meeting the 2010 ACR/EULAR criteria of RA and ACR functional class I-III,
* have =6 swollen joints (from a 66-joint count) and

=8 tender joints (from a 68-joint count) at Screening and at Baseline,
* Screening serum c-reactive protein = 0.7 x upper limit of laboratory normal range (ULN),
* have shown an inadequate response in terms of either lack of efficacy or toxicity to MTX,
* have agreed to be washed out from MTX for a period of at least 4 weeks before or during the Screening period.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* current therapy with any non-biological disease modifying anti-rheumatic drug (DMARD), with the exception of antimalarials, which must be at a stable dose for at least 12 weeks prior to Screening,
* current or previous RA treatment with a biologic DMARD, with the exception of biologic DMARDs: administered in a single clinical study setting, and; more than 6 months prior to Screening (12 months for rituximab or other B cell depleting agents), and; where the biologic DMARD was effective, and if discontinued, this should not be due to lack of efficacy,
* previous treatment at any time with a cytotoxic agent, other than MTX, before Screening.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
8/10/2013
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
29/05/2015
Sample size
Target
Accrual to date
Final
287
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Royal Prince Alfred Hospital - Camperdown
Recruitment hospital [2] 0 0
Princess Alexandra Hospital - Woolloongabba
Recruitment postcode(s) [1] 0 0
- Camperdown
Recruitment postcode(s) [2] 0 0
- Woolloongabba
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Maryland
Country [8] 0 0
United States of America
State/province [8] 0 0
Michigan
Country [9] 0 0
United States of America
State/province [9] 0 0
Nevada
Country [10] 0 0
United States of America
State/province [10] 0 0
New Jersey
Country [11] 0 0
United States of America
State/province [11] 0 0
Oklahoma
Country [12] 0 0
United States of America
State/province [12] 0 0
Pennsylvania
Country [13] 0 0
United States of America
State/province [13] 0 0
South Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
Tennessee
Country [15] 0 0
United States of America
State/province [15] 0 0
Texas
Country [16] 0 0
Argentina
State/province [16] 0 0
Lanus
Country [17] 0 0
Argentina
State/province [17] 0 0
Rosario
Country [18] 0 0
Argentina
State/province [18] 0 0
Tucuman
Country [19] 0 0
Austria
State/province [19] 0 0
Wien
Country [20] 0 0
Bulgaria
State/province [20] 0 0
Plovdiv
Country [21] 0 0
Bulgaria
State/province [21] 0 0
Sofia
Country [22] 0 0
Chile
State/province [22] 0 0
Concepcion
Country [23] 0 0
Chile
State/province [23] 0 0
Temuco
Country [24] 0 0
Colombia
State/province [24] 0 0
Barranquilla
Country [25] 0 0
Colombia
State/province [25] 0 0
Bogota
Country [26] 0 0
Colombia
State/province [26] 0 0
Bucaramanga
Country [27] 0 0
Colombia
State/province [27] 0 0
Chia
Country [28] 0 0
Germany
State/province [28] 0 0
Berlin
Country [29] 0 0
Germany
State/province [29] 0 0
Hamburg
Country [30] 0 0
Guatemala
State/province [30] 0 0
Guatemala City
Country [31] 0 0
Hungary
State/province [31] 0 0
Balatonfüred
Country [32] 0 0
Hungary
State/province [32] 0 0
Budapest
Country [33] 0 0
Hungary
State/province [33] 0 0
Veszprem
Country [34] 0 0
Latvia
State/province [34] 0 0
Liepaja
Country [35] 0 0
Latvia
State/province [35] 0 0
Riga
Country [36] 0 0
Mexico
State/province [36] 0 0
Mexico
Country [37] 0 0
Mexico
State/province [37] 0 0
Monterrey
Country [38] 0 0
Mexico
State/province [38] 0 0
Oaxaca
Country [39] 0 0
Moldova, Republic of
State/province [39] 0 0
Chisinau
Country [40] 0 0
New Zealand
State/province [40] 0 0
Auckland
Country [41] 0 0
New Zealand
State/province [41] 0 0
Timaru
Country [42] 0 0
Poland
State/province [42] 0 0
Bytom
Country [43] 0 0
Poland
State/province [43] 0 0
Elblag
Country [44] 0 0
Poland
State/province [44] 0 0
Katowice
Country [45] 0 0
Poland
State/province [45] 0 0
Krakow
Country [46] 0 0
Poland
State/province [46] 0 0
Skierniewice
Country [47] 0 0
Poland
State/province [47] 0 0
Sroda Wielkopolska
Country [48] 0 0
Poland
State/province [48] 0 0
Warsaw
Country [49] 0 0
Poland
State/province [49] 0 0
Warszawa
Country [50] 0 0
Poland
State/province [50] 0 0
Wroclaw
Country [51] 0 0
Romania
State/province [51] 0 0
Bucharest
Country [52] 0 0
Romania
State/province [52] 0 0
Bucuresti
Country [53] 0 0
Romania
State/province [53] 0 0
Galati
Country [54] 0 0
Russian Federation
State/province [54] 0 0
Orenburg
Country [55] 0 0
Russian Federation
State/province [55] 0 0
Saratov
Country [56] 0 0
Russian Federation
State/province [56] 0 0
Vladimir
Country [57] 0 0
Spain
State/province [57] 0 0
Elche
Country [58] 0 0
Spain
State/province [58] 0 0
Sabadell
Country [59] 0 0
Spain
State/province [59] 0 0
Santiago De Compostella
Country [60] 0 0
Ukraine
State/province [60] 0 0
Donetsk
Country [61] 0 0
Ukraine
State/province [61] 0 0
Kharkiv
Country [62] 0 0
Ukraine
State/province [62] 0 0
Kherson
Country [63] 0 0
Ukraine
State/province [63] 0 0
Kiev
Country [64] 0 0
Ukraine
State/province [64] 0 0
Vinnytsya

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Galapagos NV
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
* Participants suffering from active rheumatoid arthritis who had an inadequate response to methotrexate were evaluated for improvement of disease activity (efficacy) when taking GLPG0634 as monotherapy (3 different doses - 50 milligram (mg), 100 mg and 200 mg once daily) or matching placebo for 24 weeks.
* During the course of the study, patients were also examined for any side effects that could occur (safety and tolerability), and the amount of GLPG0634 present in the blood (Pharmacokinetics) as well as the effects of GLPG0634 on disease- and mechanism of action-related parameters in the blood (Pharmacodynamics) were determined. Also, the effects of different doses of GLPG0634 administration on participants' disability, fatigue and quality of life were evaluated.
Trial website
https://clinicaltrials.gov/study/NCT01894516
Trial related presentations / publications
Combe B, Besuyen R, Gomez-Centeno A, Matsubara T, Sancho Jimenez JJ, Yin Z, Buch MH. Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis. Rheumatol Ther. 2023 Feb;10(1):35-51. doi: 10.1007/s40744-022-00494-1. Epub 2022 Oct 7.
Tarrant JM, Galien R, Li W, Goyal L, Pan Y, Hawtin R, Zhang W, Van der Aa A, Taylor PC. Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials. Rheumatol Ther. 2020 Mar;7(1):173-190. doi: 10.1007/s40744-019-00192-5. Epub 2020 Jan 7.
Kavanaugh A, Kremer J, Ponce L, Cseuz R, Reshetko OV, Stanislavchuk M, Greenwald M, Van der Aa A, Vanhoutte F, Tasset C, Harrison P. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). Ann Rheum Dis. 2017 Jun;76(6):1009-1019. doi: 10.1136/annrheumdis-2016-210105. Epub 2016 Dec 19.
Public notes

Contacts
Principal investigator
Name 0 0
Galapagos Study Director
Address 0 0
Galapagos NV
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01894516